
Kim Nguyen, PharmD, discusses findings from her OPC abstract on cardiovascular toxicities and drug-drug interactions associated with BTK inhibitors, highlighting strategies for individualized treatment selection and patient monitoring.

Kim Nguyen, PharmD, discusses findings from her OPC abstract on cardiovascular toxicities and drug-drug interactions associated with BTK inhibitors, highlighting strategies for individualized treatment selection and patient monitoring.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.